1 specific lethal effects of adozelesin, a DNA-alkylating drug.

2 ajor role in MMR-dependent cell death by DNA alkylating drugs.

3 ons to isolated DNA by other carcinogens and alkylating drugs.

4 nizing radiation, ultraviolet radiation, and alkylating drugs.

5 y enhances the sensitivity of tumor cells to alkylating drugs.

6 d with the sensitivity toward venetoclax and alkylating drugs.

7 oduce DNA damage, mice were treated with the alkylating drug, 1,4-bis[N,N'-di(ethylene)-phosphamide]p

8  Gy [13.0] for women), and chemotherapy with alkylating drugs (26 [2%] of 1195 women, 0.9 [0.5-1.5];

9                Greater doses of contemporary alkylating drugs and cisplatin were associated with a de

10 g Rnf4 are hypersensitive to hyroxyurea, DNA alkylating drugs and DNA crosslinking agents, but this s

11 gammaglobulinemia, conventional therapy with alkylating drugs, and recently, purine analogs and mAb-a

12  18 times more sensitive to Bizelesin, a DNA alkylating drug compared to WT parasites as reflected by

13 ression and restores chemosensitivity of DNA-alkylating drugs in mouse models.

14 ease in children and parental treatment with alkylating drugs or preconception radiation doses to the

15 ement of pro- and anti-apoptotic proteins in alkylating drug resistance of tumor cells, we utilized t

16 melanoma therapy with temozolomide and other alkylating drugs suggests a combination approach where c

17 contribute to resistance of melanomas to the alkylating drugs temozolomide, dacarbazine, and fotemust

18 nced the ability of either p53 activation or alkylating drug therapy to induce tumor cell death.

19 MDS after current or previous treatment with alkylating drugs were selected for evaluation by chart r

20  system might be sensitive to treatment with alkylating drugs whose toxicity depends on repair of thi